AI assistant
Sending…
Tempest Therapeutics, Inc. — Director's Dealing 2014
Dec 11, 2014
34632_dirs_2014-12-11_5fcc5d88-ff49-498c-a756-cfb20699c17c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-12-08
Reporting Person: Harding David (Chief Commercial Officer)
More from Tempest Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Board/Management Information
2026
May 29
Delisting Announcement
2026
May 22
Board/Management Information
2026
May 22
Interim / Quarterly Report
2026
May 14
Earnings Release
2026
May 14
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Apr 10
Capital/Financing Update
2026
Apr 10
Regulatory Filings
2026
Mar 31